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With more than 6000 patients treated and with 70% to 75% ofthese patients having a significant improvement in theirangina symptoms, one would think that the mechanismwhereby transmyocardial laser revascularization (TMLR)achieves its effect would be well understood. Of the manypossible mechanisms, including angiogenesis, channel
patency, alterations of ventricular compliance, placebo effect, and denervation, it is
the latter that is the most difficult to prove or disprove. Clinical studies have indi-
rectly demonstrated that denervation does not play the primary role, a virtue of
improvement in perfusion, as demonstrated by nuclear spec scans and positron
emission tomograpic scans.1-5 Additionally, functional improvement with dobuta-
mine stress echocardiography6 and cine magnetic resonance imaging7 also indicates
that denervation is not the contributing mechanism. Furthermore, there is no signif-
icant increase in the number of acute myocardial infarctions postoperatively, despite
a significant increase in exercise tolerance and activity levels.
In this issue, Minisi and associates8 have reported on an elegant set of experi-
ments designed to evaluate the effect of TMLR on reflexes mediated by left ven-
tricular receptors with sympathetic afferent fibers. Their results indicate that TMLR
does not acutely interrupt the afferent nerves, which transmit the perception of angi-
nal pain. These results are somewhat different from others that have been reported,
and this is due to Minisi and colleagues’ efforts to isolate the reflex responses by
using an animal preparation with sinoaortic denervation and vagotomy. As a result,
they were also able to demonstrate that the reflex circuitry was completely intact
after TMLR. However, as the authors note, a major limitation of this study is that
these results are from normal canine myocardium and may not be applicable to
ischemic myocardium in human subjects. It does demonstrate that the amount of
damage inflicted by TMLR is not enough to denervate normal myocardium.
The question of the extent of laser-induced injury and the ensuing response is an
important one. Recently, attempts to perform laser revascularization percutaneously
with a catheter have met with mixed results.9-11 In fact, a placebo-controlled trial
has demonstrated no benefit of percutaneous myocardial laser revascularization.11
The revascularization that can be achieved percutaneously is limited because of the
delivery of the laser energy to a very thin layer of the subendocardium (2-3 mm)
and the difficulty with navigating the catheter within the ventricle to provide an ade-
quate distribution of the laser treatment. One other factor that may play a role is the
type of laser light that is used. Minisi and associates have used a holmium:YAG
laser. This laser is delivered through a fiber, which is manually advanced through
the myocardium. However, it is unknown whether the injury created is principally
caused by a mechanical effect of the fiber or caused by laser ablation. In the beat-
ing heart it is impossible to ensure that a fiber pushed by hand is advancing behind
the wave of laser ablation. It would therefore be of interest to perform further exper-
iments, not only in an ischemic model but also using the fiber alone or using other
types of laser light that are not dependent on fiber delivery (for example, carbon
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dioxide) to confirm their results and provide clinical corre-
lation. This difference in laser light has become clinically
apparent over the long term because those treated with a
holmium:YAG laser have had a significant increase in
angina over 3 years after treatment.11 In contrast, patients
treated with carbon dioxide TMLR have continued angina
relief over 5 years after treatment.13
Demonstrating that TMLR does not denervate the heart
is an important piece of the mechanistic puzzle.
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